Fenofibric acid, an active form of fenofibrate that is marketed as Trilipix, may not reduce the risk of heart attack or stroke, according to a Nov. 9 FDA safety announcement. Family physicians may wish to notify their patients that although the drug has not been shown to lower these cardiovascular risks, patients should not stop taking the medication without first consulting their physician.
Creating memories for families by sharing information relating to children and parents with regard to activities, products, school, home and more.
Trilipix Efficacy in Question, Says FDA
- Login or register to post comments
- Feed: Health of the Public
- Original article